More on SHPGY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SHPGY Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 324.4M
Share based compensation 77.4M
Gain on sale of non-current investments 0
Other
Movement in deferred taxes -349.9M
Equity in earnings of equity method investees -3.9M
Loss/(gain) on sale of product rights -15.9M
Changes in operating assets and liabilities:
Increase in accounts receivable -148.3M
Increase in sales deduction accrual 177.5M
Increase in inventory -36.6M
Increase in prepayments and other assets -60.9M
Decrease in accounts payable and other liabilities 67.9M
Net cash provided by operating activities 1.46B
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash -5.3M
Purchases of subsidiary undertakings, net of cash acquired -227.8M
Purchases of non-current investments -10.6M
Purchases of property, plant and equipment ("PP&E") -157M
Purchases of intangible assets 0
Proceeds from disposal of non-current investments, PP&E and product rights 12.1M
Returns of equity investments and proceeds from short term investments
Net cash used in investing activities -360.9M
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawings of revolving credit facility 0
Repayment of debt acquired with ABH 0
Payment under building finance obligation
Extinguishment of building finance obligation
Tax benefit of stock based compensation 13.4M
Proceeds from exercise of options 17.2M
Payment of dividend -96.4M
Payments to acquire shares by ESOT
Net cash used in financing activities -344.6M
Net (decrease)/increase in cash and cash equivalents 757.2M
Effect of foreign exchange rate changes on cash and cash equivalents -300K
Cash and cash equivalents at beginning of period 1.48B
Cash and cash equivalents at end of period 2.24B
Supplemental information associated with continuing operations:
Interest paid -29.9M
Income taxes paid -290.2M
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment